MEND-PNPONCT04706013
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
At risk: Primary completion moved at least 9 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 11 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 7 → 10 locations
- Notable Primary and study completion pushed from Nov 2026 to Sep 2027
- Eligibility criteria expanded, about 6 words
- Enrollment closed, study ongoing
- Site details revised at 7 of 7 sites
- Notable Eligibility criteria expanded, about 5 words
- Study sites: 6 to 7
- Notable Primary and study completion dates: May 2025 to Nov 2026v8
- Minor Study sites: 5 to 6v7
Show 5 earlier versionsHide 5 earlier versions
- Minor Study sites: 2 to 5v6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 2
- Primary completion date: Feb 2025 to May 2025
- Start date changed from estimate of Jan 2024 to Feb 16, 2024
- Notable Primary completion date: Nov 2023 to Feb 2025
- Start date: Oct 2022 to Jan 2024
- Study sites: 0 to 1
- Study completion date: Nov 2023 to May 2025
- Notable Primary and study completion dates: Nov 2022 to Nov 2023
- Start date: Oct 2021 to Oct 2022
- Notable Primary and study completion dates: Apr 2022 to Nov 2022
- Start date: Mar 2021 to Oct 2021
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Overall survival time (time to death), including incidence of death at 12 months
Timeframe: 12 months
Secondary (1)
Frequency of seizures (including but not limited to status epilepticus)
Arms and interventions
Single Arm ActiveExperimental
Pyridoxal 5'-Phosphate
Drugs: Pyridoxal Phosphate
Sites
10 sites in 3 countries
United States 6, Poland 3, Australia 1